Abstract
Baseline CD4 cell counts and human immunodeficiency virus (HIV)-1 RNA levels have been shown to predict immunologic and virologic responses in HIV-infected patients receiving antiretroviral therapy. In our randomized, double-blind, comparative trial, 653 antiretroviral therapy-naive patients received lopinavir/ritonavir or nelfinavir, plus stavudine and lamivudine, for up to 96 weeks. The risk of loss of virologic response was significantly higher for nelfinavir-treated patients than for lopinavir/ritonavir-treated patients (Cox model hazard ratio, 2.2; 95% confidence interval, 1.7-3.0; P<.001). For nelfinavir-treated patients, but not for lopinavir/ritonavir-treated patients, higher baseline HIV-1 RNA levels and lower baseline CD4 cell counts were associated with a higher risk of loss of virologic response.
Publication types
- Clinical Trial
- Clinical Trial, Phase III
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
MeSH terms
- Anti-HIV Agents / pharmacology
- Anti-HIV Agents / therapeutic use*
- CD4 Lymphocyte Count
- Double-Blind Method
- Drug Resistance, Viral
- Drug Therapy, Combination
- Female
- HIV Infections / drug therapy*
- HIV Infections / immunology
- HIV Infections / virology
- HIV-1 / drug effects*
- Humans
- Lamivudine / therapeutic use
- Lopinavir
- Male
- Nelfinavir / pharmacology
- Nelfinavir / therapeutic use*
- Predictive Value of Tests
- Pyrimidinones / pharmacology
- Pyrimidinones / therapeutic use*
- RNA, Viral / blood
- Risk Factors
- Ritonavir / pharmacology
- Ritonavir / therapeutic use*
- Sex Characteristics
- Stavudine / therapeutic use
- Viral Load
Substances
- Anti-HIV Agents
- Pyrimidinones
- RNA, Viral
- Lopinavir
- Lamivudine
- Stavudine
- Nelfinavir
- Ritonavir